Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

Inclusion Criteria: 1. Histologically or cytologically confirmed, or imaging diagnosed HCC 2. HLA-A \*02 genotyping 3. HBsAg positive in serum or tumor tissue 4. Have at least one measurable lesion at baseline as per mRECIST and RECIST v1.1 criteria 5. Child-Pugh score ≤ 7 6. ECOG performance status of 0 or 1 7. Life expectancy of 3 months or greater 8. Patient with adequate organ function Exclusion Criteria: 1. Uncontrolled portal vein or inferior vena cava tumor thrombosis 2. Untreated or active Central nervous system (CNS) metastasis or other clinically significant CNS diseases 3. Active or uncontrollable infections 4. History of organ transplantation 5. Lack of peripheral or central venous access or any condition that would interfere with study drug administration or collection of study sample 6. History of positive results for human immunodeficiency virus (HIV) 1 or 2 or known acquired immunodeficiency syndrome (AIDS) 7. Prior exposure to any cell therapy 8. Other severe medical conditions that may limit subject's participation in this trial